Table 6.
Univariate and Multivariate Analysis of Risk Factors for Advanced Fibrosis
| Univariate | Multivariate Model 1 | |||
|---|---|---|---|---|
| OR (95% CI) | P | aOR (95% CI) | P | |
| Age | 1.03 (1.00–1.07) | .085 | … | |
| BMI | 1.04 (.97–1.12) | .242 | … | |
| Black ethnicity | .14 (.02–1.14) | .066 | … | |
| NAFLD | 2.56 (1.14–5.78) | .023 | 2.47 (.96–6.39) | .062 |
| Type 2 diabetes | 5.26 (2.05–13.50) | .001 | 3.42 (1.00–11.71) | .050 |
| Hypertension | 2.65 (1.20–5.85) | .016 | .99 (.34–2.89) | .983 |
| Dyslipidemia | 3.12 (1.40–6.94) | .005 | 1.88 (.69–5.13) | .221 |
| Duration of ART | 1.06 (1.00–1.11) | .036 | 1.03 (.97–1.09) | .394 |
| D-drugsa | 1.82 (.80–4.12) | .152 | … | |
| CD4 | 1.71 (.76–3.86) | .195 | … | |
| CD8 | 1.00 (1.00–1.00) | .124 | … | |
| CD4 nadir | 1.00 (1.00–1.00) | .205 | … | |
| Time since HIV infection | 1.08 (1.03–1.13) | .002 | … | |
Multivariate model: BMI (per kg/m2), NAFLD (≥5% steatosis on liver biopsy), type 2 diabetes, hypertension, dyslipidemia, duration of ART (per year).
Abbreviations: aOR, adjusted odds ratio; ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; D-drug; dideoxynucleoside analog; HIV, human immunodeficiency virus; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio.
aPast exposure in lifetime.